meglumine has been researched along with Leishmaniasis in 122 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 44 (36.07) | 18.7374 |
1990's | 22 (18.03) | 18.2507 |
2000's | 26 (21.31) | 29.6817 |
2010's | 30 (24.59) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Damrose, E; Fernandes, AM; Silva, L | 1 |
Burchmore, R; Ceron, JJ; Escribano, D; Horvatic, A; Kocaturk, M; Martinez-Subiela, S; Mrljak, V; Pardo-Marin, L; Yilmaz, Z | 1 |
Akhtar, S; Ashraf, S; Hussain, I; Hussain, SZ; Rafay, M; Sarwar, HS; Shahnaz, G; Sohail, MF; Yasinzai, M | 1 |
Cantos-Barreda, A; Cerón, JJ; Escribano, D; Martínez-Subiela, S; Pardo-Marín, L; Segarra, S | 1 |
Ibba, F; Mangiagalli, G; Paltrinieri, S | 1 |
Andrade, HF; Borborema, SE; Nascimento, Nd; Osso, JA | 1 |
Giordano, A; Ibba, F; Meazzi, S; Paltrinieri, S; Rossi, G | 1 |
Diaz-Toro, Y; Fernández, OL; Gomez, MA; Muvdi, S; Ovalle, C; Rodríguez, I; Saravia, NG; Valderrama, L | 1 |
Baptista, C; Conceição-Silva, F; Leon, LL; Madeira, Mde F; Miranda, Lde F; Schubach, Ade O | 1 |
Cerrone, A; Corso, R; Galiero, G; Gravino, AE; Manna, L; Muzj, P | 1 |
Fernández, OL; Gonzalez-Fajardo, L; McMahon-Pratt, D; Saravia, NG | 1 |
Acedo-Sánchez, C; Corpas-López, V; Díaz-Sáez, V; Martín-Sánchez, J; Merino-Espinosa, G; Morillas-Márquez, F | 1 |
Alborch, L; Montserrat-Sangrà, S; Ordeix, L; Solano-Gallego, L | 1 |
Ceron, JJ; Hernández-Ruiz, J; Martinez-Subiela, S; Pardo-Marin, L; Rubio, CP; Segarra, S; Tvarijonaviciute, A | 1 |
Cerón, JJ; Escribano, D; Kocaturk, M; Martínez-Subiela, S; Pardo-Marín, L; Torrecillas, A; Tvarijonaviciute, A; Yilmaz, Z | 1 |
Abamor, ES; Allahverdiyev, AM; Bagirova, M; Rafailovich, M | 1 |
Cerón, JJ; Garcia-Martinez, JD; Martínez-Subiela, S; Pardo-Marín, L; Pastor, J; Segarra, S; Tvarijonaviciute, A | 1 |
De Majo, M; Lo Giudice, S; Masucci, M; Pennisi, MG; Reale, S; Vitale, F | 1 |
de Paula-Coelho, VN; Muniz-Junqueira, MI | 1 |
Foglia Manzillo, V; Gradoni, L; Guglielmino, R; Oliva, G; Pagano, A; Restucci, B | 1 |
Bianciardi, P; Mateo, M; Maynard, L; Miró, G; Vischer, C | 1 |
Arnedo-Pena, A; Bellido-Blasco, JB; Herrero-Carot, C; Romeo-García, MA | 1 |
Bertazzolo, W; Dell'Orco, M; Paccioretti, F | 1 |
Boutaleb-Charki, S; Díaz, JG; Guitierrez-Sánchez, R; Huertas, O; Marín, C; Pérez-Cordon, G; Rosales, MJ; Sánchez-Moreno, M | 1 |
Aresu, L; Bianciardi, P; Brovida, C; Castagnaro, M; Cavicchioli, L; Giroud, L; Valente, M; Vischer, C | 1 |
Lamothe, J | 1 |
Cavassini, M; Cometta, A; Foguena, AK; Greub, G; Schroeder, D | 1 |
Bardagí, M; Ferrer, L; Ravera, I; Roura, X; Torres, M; Zanna, G | 1 |
Hajiabdolbaghi, M; Hajjaran, H; Hashemian, H; Jafari, S; Mohebali, M | 1 |
Demicheli, C; Frézard, F | 1 |
Dobakhti, F; Khalili, G; Khaze, V; Mahmoudzadeh-Niknam, H; Partovi, F | 1 |
Descalzo, MA; Fraile, C; Gálvez, R; Miró, G; Molina, R | 1 |
Borborema, SE; de Andrade, HF; do Nascimento, N; Osso, JA; Schwendener, RA | 1 |
Amato, ME; De Palo, P; Greco, B; Lubas, G; Paradies, P; Sasanelli, M | 1 |
Castillo, H; Diaz-Toro, Y; Fernández, O; Ovalle, C; Perez, M; Saravia, NG; Valderrama, L; Valderrama, M | 1 |
Forouzannia, SK; Pourrajab, F; Tabatabaee, SA | 1 |
Baker, NC; Blanco, V; Craft, N; Garcerant, D; Martinez, J; Rubiano, L | 1 |
Calla-Magariños, J; Fernández, C; Freysdottir, J; Giménez, A; Quispe, T; Troye-Blomberg, M | 1 |
Almeida Catanho, MT; Amorim, LF; Bernardo-Filho, M; Brandao, KC; Cavalcanti Jales, RL; de Brito Tiago, GG; Gomes, ML; Holanda Leite, RC; Jales-Junior, LH; Lopes de Brito, LM; Xavier Holanda, CM | 1 |
Alvarez, N; Le Baut, G; Le Pape, P; Robert, JM; Robledo, S; Velez, ID | 1 |
NOGUER MORE, S | 1 |
BOIX BARRIOS, J | 1 |
BERNARD, R; GIRAUD, P; VINCENT, P | 1 |
FLOCH, H | 1 |
CORNEJO, A | 2 |
MATOS, J; VELASCO, JA | 1 |
CARVALHO, O | 1 |
PI FERRER, A; SALA GINABREDA, JM; WOESSNER CASAS, S | 1 |
CAMBI, P | 1 |
ESCHER, D; LAHAM, E | 1 |
DURAND, P | 1 |
BOULARD, C; MASSONNAT, J; PORTIER, A | 1 |
RIPA, F; TONDI, IV | 1 |
Diaz-Bertrana, MC; Durall, I; Franch, J; Lafuente, P; Munilla, A; Pastor, J; Torrent, E | 1 |
Arango, G; Jaramillo, LM; Muñoz, D; Osorio, E; Restrepo, A; Robledo, S; Vélez, I | 1 |
Aceña, MC; Castillo, JA; Gascón, M; Gómez-Ochoa, P; Miana-Mena, FJ | 1 |
de Oliveira, FB; Demicheli, C; Dzamitika, SA; Falcão, CA; Frézard, F; Garnier-Suillerot, A; Marbeuf, C; Rossi-Bergmann, B | 1 |
de Castro Pimenta, AM; Demicheli, C; dos Santos Ferreira, C; Frézard, F | 1 |
Cortes, S; João, A; Pereira, MA; Santos-Gomes, GM | 1 |
Soto, J; Soto, P | 1 |
Bouvresse, S; Crickx, B; Descamps, V; Devillière, M; Mahé, E; Marinho, E; Matichard, E; Soria, A | 1 |
Gravino, AE; Manna, L; Pavone, LM; Picillo, E; Reale, S; Vitale, F | 1 |
de Moura, FJ; de Souza Furtado, R; Leal, PP; Muniz-Junqueira, MI; Veiga, JP | 1 |
Baron, AR; Del Pilar Mahecha, M; Dueñes, B; Montaña, R; Montero, LM; Reithinger, R; Sanchez, BF; Vega, JC | 1 |
Alonso, C; Castilla, J; Fuertes, MA; Nguewa, PA; Pérez, JM | 1 |
Steck, EA | 1 |
Fisher, BK; Schewach-Millet, M; Semah, D | 1 |
Freeman, K | 1 |
Heimgartner, E | 1 |
Hidalgo, H; Solano, E; Zeledón, R | 1 |
Armas, JA; Moreno, G; Rezzano, S; Scorza, JV | 1 |
Chapman, WL; Hanson, WL; Hendricks, LD | 1 |
Avila, JL; Biondo, F; Convit, J; Monzón, H | 1 |
Belloli, C; Carli, S; Ceci, L; De Natale, G; Marcotrigiano, G; Montesissa, C; Ormas, P; Tassi, P | 1 |
Cánovas Llorens, DL; Carbonell Casasús, J; Mas Mercant, S; Soler Vilarrasa, R | 1 |
Añez, N; Burguera, JL; Burguera, M; Lugo de Yarbuh, A; Petit de Peña, Y | 1 |
Evans, TG | 1 |
Barbieri, CL; Cantos, G; Gorin, PA; Iacomini, M; Travassos, LR | 1 |
Barrios, AA; Bruneton, J; Cavé, A; Fournet, A; Hocquemiller, R; Muñoz, V | 1 |
Evans, TG; Hibbs, JB; Reed, SS | 1 |
Slappendel, RJ; Teske, E | 1 |
Alberola, J; Arboix, M; Cristofol, C; Franquelo, C; Freixas, J; Valladares, JE | 1 |
García Salazar, MA; Jiménez Martín, MJ; López Martínez, J; Temprano Vázquez, S | 1 |
Amusategui, I; Sainz, A; Tesouro, MA | 1 |
Agostoni, C; Dorigoni, N; Malfitano, A; Migliorini, D; Scaglia, M | 1 |
Carvalho, S; de Figueiredo, TL; Demicheli, C; Frézard, F; Lopes, JC; Sinesterra, RD | 1 |
Atienza Fernández, F; Castelló Viguer, MT; Cuesta Estellés, G; Echánove Errazti, I; Esteban Esteban, E; Ridocci Soriano, F | 1 |
Panadés, MJ; Porcel, JM; Rubio, M; Sacristán, O | 1 |
Miekeley, N; Mortari, SR; Schubach, AO | 1 |
Aste, N; Biggio, P; Pau, M | 1 |
Carrió, J; Portús, M | 1 |
Alving, CR; Chapman, WL; Hanson, WL; Hendricks, LD; Steck, EA; Swartz, GM; Waits, VB | 1 |
Alving, CR; Chapman, WL; Hanson, WL; Loizeaux, PS; Steck, EA; Waits, VB | 1 |
Kürkçüoğlu, N; Tandoğdu, R | 1 |
Ellis, WY; Jackson, JE; Lawyer, PG; Limmer, BL; Mebrahtu, YB; Panisko, DM; Reed, SG; Tally, JD; Were, JB | 1 |
Dedet, JP | 1 |
De Rivera, MV; Franke, ED; Kruger, JH; Lucas, CM; Tovar, AA; Wignall, FS | 1 |
Goerttler, E; Krutmann, J; Rzany, B; Schöpf, E | 1 |
Dorea, JG; Holzbecher, J; Merchan-Hamann, E; Ryan, DE | 1 |
Hanson, WL; Klayman, DL; Lovelace, JK; Vennerstrom, JL; Waits, VB | 1 |
Arana, BA; Arana, FE; Castillo, AL; de Mérida, AM; Navin, TR; Pozuelos, JL | 1 |
Walton, BC | 1 |
Vion, B | 1 |
Jackson, JE; Tally, JD; Tang, DB | 1 |
Castellanos, PL; Castes, M; Convit, J; Martinez, A; Moros, Z; Rondon, AJ; Trujillo, D | 1 |
de Vásquez, AM; Johnson, CM; Narvaez, E; Paz, HM; Sáenz, RE | 1 |
Marsden, PD; Sampaio, JH; Sampaio, RN | 1 |
Santrich, C; Saravia, NG; Valderrama, L; Weigle, KA | 1 |
Bloom, B; Castellanos, PL; Castes, M; Convit, J; Garcia, L; Pinardi, ME; Rondon, A; Ulrich, M | 1 |
Kumar, PV; Sadeghi, E; Torabi, S | 1 |
Anciaux, ML; Bourée, P; Taugourdeau, P | 1 |
Chong, H | 1 |
Lambert, D; Mambre, B | 1 |
Benderitter, T; Casanova, P; Nashkidachvili, L; Quilici, M | 1 |
Castro Coto, A; Coto Chacón, F; Hidalgo Hidalgo, H; Solano Aguilar, E | 1 |
Desjeux, P; Le Pont, F; Mollinedo, S; Paredes, A; Ugarte, G | 1 |
Alfred, C; Brandicourt, O; Gentilini, M; Mazier, D; Monjour, L; Nzuzi, KK; Ploton, I; Tselentis, Y; Vouldoukis, I | 1 |
Belazzoug, S; Neal, RA | 1 |
Aranzazu, N; Castellanos, PL; Convit, J; Pinardi, ME; Reyes, O; Ulrich, M | 1 |
el-On, J; Kernbaum, S; Rubinstein, N; Schnur, LF | 1 |
Barral, A; Barreto, AC; Carvalho, EM; Costa, JM; Cuba, CC; Llanos-Cuentas, EA; Magalhães, AV; Marsden, PD; Netto, EM; Rosa, AC | 1 |
9 review(s) available for meglumine and Leishmaniasis
Article | Year |
---|---|
New delivery strategies for the old pentavalent antimonial drugs.
Topics: Administration, Oral; Administration, Topical; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Drug Delivery Systems; Humans; Leishmaniasis; Liposomes; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2010 |
[Current situation and future of antileishmanial therapy in Colombia].
Topics: Antimony; Antiprotozoal Agents; Colombia; Forecasting; Humans; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2006 |
Anticancer compounds as leishmanicidal drugs: challenges in chemotherapy and future perspectives.
Topics: Amsacrine; Animals; Antineoplastic Agents; Antiprotozoal Agents; Apoptosis; Humans; Leishmania; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Organoplatinum Compounds; Oxyquinoline; Phospholipids; Topoisomerase II Inhibitors | 2008 |
The chemotherapy of protozoal infections: whither?
Topics: Animals; Antimony; Antimony Sodium Gluconate; Antiprotozoal Agents; Disease Models, Animal; Glycolipids; Humans; Leishmaniasis; Leishmaniasis, Visceral; Liposomes; Lysosomes; Malaria; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Primaquine; Protozoan Infections; Trypanosomiasis | 1981 |
American cutaneous leishmaniasis.
Topics: Antimony; Antimony Sodium Gluconate; Antiparasitic Agents; Antiprotozoal Agents; Belize; Central America; Diagnosis, Differential; Humans; Leishmaniasis; Meglumine; Military Medicine; Skin Diseases, Parasitic; South America; United Kingdom | 1983 |
Leishmaniasis.
Topics: Adult; AIDS-Related Opportunistic Infections; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Child, Preschool; Female; Humans; Leishmania; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Protozoan Vaccines; Vaccination | 1993 |
Cutaneous leishmaniasis in French Guiana: a review.
Topics: Animals; Antiprotozoal Agents; Disease Reservoirs; French Guiana; Humans; Insect Vectors; Leishmania braziliensis; Leishmania mexicana; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Psychodidae | 1990 |
Oriental sore. A look at trends in and approaches to the treatment of leishmaniasis.
Topics: Allopurinol; Aminoquinolines; Antimony; Antimony Sodium Gluconate; Cryosurgery; Humans; Leishmaniasis; Leishmaniasis, Mucocutaneous; Levamisole; Liposomes; Meglumine; Meglumine Antimoniate; Metronidazole; Nifurtimox; Organometallic Compounds; Phenothiazines; Rifampin | 1986 |
[Treatment of cutaneous leishmaniasis].
Topics: Antiprotozoal Agents; Humans; Hyperthermia, Induced; Immunotherapy; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1988 |
8 trial(s) available for meglumine and Leishmaniasis
Article | Year |
---|---|
Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leishmania; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine; Retrospective Studies | 2015 |
Clinical efficacy of two different drug combinations for the treatment of canine leishmaniasis.
Topics: Animals; Antibodies, Protozoan; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Leishmaniasis; Meglumine; Meglumine Antimoniate; Metronidazole; Organometallic Compounds; Spiramycin; Treatment Outcome | 2008 |
Monitoring the reverse to normal of clinico-pathological findings and the disease free interval time using four different treatment protocols for canine leishmaniosis in an endemic area.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Endemic Diseases; Female; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Time Factors | 2012 |
The effect of intravenous or subcutaneous administration of meglumine antimonate (Glucantime) in dogs with leishmaniasis. A randomized clinical trial.
Topics: Animals; Antimony; Antiprotozoal Agents; Disease-Free Survival; Dog Diseases; Dogs; Female; Injections, Intravenous; Injections, Subcutaneous; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Recurrence; Remission Induction; Treatment Outcome | 1997 |
Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala.
Topics: Adult; Animals; Antimony; Antiprotozoal Agents; Follow-Up Studies; Guatemala; Hot Temperature; Humans; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Military Personnel; Organometallic Compounds; Radio Waves; Randomized Controlled Trials as Topic; Sorbitol | 1990 |
Cell-mediated immunity in localized cutaneous leishmaniasis patients before and after treatment with immunotherapy or chemotherapy.
Topics: Adult; Antigens, Protozoan; BCG Vaccine; Clinical Trials as Topic; Female; Humans; Immunity, Cellular; Immunotherapy; Leishmaniasis; Leukocytes; Lymphocyte Activation; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Skin Tests | 1989 |
Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis.
Topics: Adolescent; Adult; Antibodies; Antigens, Protozoan; Antiprotozoal Agents; Child; Clinical Trials as Topic; Female; Humans; Immunotherapy; Leishmania mexicana; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Mycobacterium bovis; Organometallic Compounds; Random Allocation; Skin Tests; Sorbitol; Vaccination | 1987 |
Failure of meglumine antimoniate to cure cutaneous lesions due to Leishmania major in Algeria.
Topics: Adolescent; Algeria; Antimony; Antiprotozoal Agents; Child; Clinical Trials as Topic; Humans; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1986 |
105 other study(ies) available for meglumine and Leishmaniasis
Article | Year |
---|---|
Laryngeal leishmaniasis, a rare manifestation of an emerging disease.
Topics: Animals; Antiprotozoal Agents; Communicable Diseases, Emerging; Emergencies; Hoarseness; Humans; Laryngeal Diseases; Leishmania braziliensis; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Nasal Obstruction; Organometallic Compounds; Psychodidae; Tracheostomy; Treatment Outcome | 2017 |
Identification of novel biomarkers for treatment monitoring in canine leishmaniosis by high-resolution quantitative proteomic analysis.
Topics: Acute-Phase Proteins; Allopurinol; Animals; Antiprotozoal Agents; Biomarkers; Dog Diseases; Dogs; Female; Ferritins; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Proteomics; Serum Globulins | 2017 |
Mannosylated thiolated polyethylenimine nanoparticles for the enhanced efficacy of antimonial drug against Leishmaniasis.
Topics: Antiprotozoal Agents; Biological Transport; Chitosan; Drug Carriers; Drug Liberation; Humans; Leishmania; Leishmaniasis; Mannose; Meglumine; Meglumine Antimoniate; Nanoparticles; Organometallic Compounds; Particle Size; Polyethyleneimine; Sulfhydryl Compounds; Surface Properties | 2018 |
Changes in serum anti-Leishmania antibody concentrations measured by time-resolved immunofluorometric assays in dogs with leishmaniosis after treatment.
Topics: Allopurinol; Animals; Antibodies, Protozoan; Antiprotozoal Agents; Dog Diseases; Dogs; Enzyme-Linked Immunosorbent Assay; Fluoroimmunoassay; Immunoglobulin A; Immunoglobulin G; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Treatment Outcome | 2018 |
Use of urinary γ-glutamyl transferase (GGT) to monitor the pattern of proteinuria in dogs with leishmaniasis treated with N-methylglucamine antimoniate.
Topics: Animals; Creatinine; Dog Diseases; Dogs; gamma-Glutamyltransferase; Leishmaniasis; Meglumine; Proteinuria | 2018 |
Biodistribution of meglumine antimoniate in healthy and Leishmania (Leishmania) infantum chagasi-infected BALB/c mice.
Topics: Animals; Antimony; Antiprotozoal Agents; Cricetinae; Female; Leishmania infantum; Leishmaniasis; Meglumine; Meglumine Antimoniate; Mice, Inbred BALB C; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Time Factors; Tissue Distribution | 2013 |
Paraoxonase activity as a tool for clinical monitoring of dogs treated for canine leishmaniasis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Aryldialkylphosphatase; Biomarkers; Case-Control Studies; Dog Diseases; Dogs; Drug Therapy, Combination; Enzyme Activation; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2014 |
Miltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in Colombia.
Topics: Adolescent; Adult; Aged; Antimony; Child; Child, Preschool; Cohort Studies; Colombia; Drug Resistance; Humans; Infant; Leishmania; Leishmaniasis; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Phosphorylcholine; Randomized Controlled Trials as Topic; Young Adult | 2014 |
In vitro sensitivity of paired Leishmania (Viannia) braziliensis samples isolated before meglumine antimoniate treatment and after treatment failure or reactivation of cutaneous leishmaniasis.
Topics: Adolescent; Adult; Aged; Antiprotozoal Agents; Female; Humans; Leishmania braziliensis; Leishmaniasis; Lethal Dose 50; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Skin | 2015 |
Ex vivo host and parasite response to antileishmanial drugs and immunomodulators.
Topics: Adolescent; Animals; Antiprotozoal Agents; Female; Humans; Immunologic Factors; Interferon-alpha; Interleukin-10; Interleukin-13; Leishmania; Leishmaniasis; Leukocytes, Mononuclear; Macrophages; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine; Tumor Necrosis Factor-alpha; Young Adult | 2015 |
Hair parasite load as a new biomarker for monitoring treatment response in canine leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Biomarkers; Dog Diseases; Dogs; Hair; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Parasite Load | 2016 |
TLR-2 and TLR-4 transcriptions in unstimulated blood from dogs with leishmaniosis due to Leishmania infantum at the time of diagnosis and during follow-up treatment.
Topics: Allopurinol; Animals; Antibodies, Protozoan; Antiprotozoal Agents; Dog Diseases; Dogs; Female; Follow-Up Studies; Leishmania infantum; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Parasite Load; Parasitemia; Toll-Like Receptor 2; Toll-Like Receptor 4; Up-Regulation | 2016 |
Changes in serum biomarkers of oxidative stress after treatment for canine leishmaniosis in sick dogs.
Topics: Animals; Antiprotozoal Agents; Aryldialkylphosphatase; Biomarkers; C-Reactive Protein; Dog Diseases; Dogs; Female; Ferritins; Gluconates; Leishmaniasis; Male; Meglumine; Oxidative Stress; Sulfhydryl Compounds | 2016 |
Serum apolipoprotein-A1 as a possible biomarker for monitoring treatment of canine leishmaniosis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Apolipoprotein A-I; Biomarkers; Dogs; Electrophoresis, Gel, Two-Dimensional; Leishmaniasis; Mass Spectrometry; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Proteome | 2016 |
Meglumine antımoniate-TiO2@Ag nanoparticle combinations reduce toxicity of the drug while enhancing its antileishmanial effect.
Topics: Animals; Antiprotozoal Agents; Cell Line; Leishmania tropica; Leishmaniasis; Macrophages; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Nanoparticles; Organometallic Compounds; Titanium | 2017 |
Evaluation of various biomarkers for kidney monitoring during canine leishmaniosis treatment.
Topics: Allopurinol; Animals; Antimetabolites; Antiprotozoal Agents; Biomarkers; Dog Diseases; Dogs; Drug Therapy, Combination; Kidney Diseases; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Proteinuria | 2017 |
Meglumine antimonate directly increases phagocytosis, superoxide anion and TNF-alpha production, but only via TNF-alpha it indirectly increases nitric oxide production by phagocytes of healthy individuals, in vitro.
Topics: Adult; Antiprotozoal Agents; Female; Humans; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Monocytes; Neutrophils; Nitric Oxide; Organometallic Compounds; Phagocytosis; Superoxides; Tumor Necrosis Factor-alpha | 2008 |
Extranodal gammadelta-T-cell lymphoma in a dog with leishmaniasis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Leishmaniasis; Lymphoma, T-Cell; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2008 |
Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Bone Marrow; Dog Diseases; Dogs; Female; Injections, Subcutaneous; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine | 2009 |
[Leishmaniasis: hospital and population-based incidence, and asymptomatic infection. A disease that is still with us].
Topics: Animals; Antiprotozoal Agents; Comorbidity; Disease Reservoirs; Dog Diseases; Dogs; Drug Utilization; HIV Infections; Humans; Incidence; Leishmaniasis; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Spain | 2009 |
What is your diagnosis? Peritoneal effusion from a dog.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Ascitic Fluid; Dog Diseases; Dogs; Female; Leishmania; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2009 |
Antileishmaniasis activity of flavonoids from Consolida oliveriana.
Topics: Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Female; Flavonoids; Galactosides; Kaempferols; Leishmania; Leishmaniasis; Meglumine; Meglumine Antimoniate; Molecular Structure; Organometallic Compounds; Ranunculaceae; Rats; Rats, Inbred Strains; Turkey | 2009 |
Administration of miltefosine and meglumine antimoniate in healthy dogs: clinicopathological evaluation of the impact on the kidneys.
Topics: Animals; Antiprotozoal Agents; Body Weight; Dogs; Female; Fluorescent Antibody Technique; Histocytochemistry; Kidney; Kidney Diseases; Kidney Tubules; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Microscopy, Electron; Organometallic Compounds; Phosphorylcholine; Random Allocation; Toxicity Tests | 2009 |
Some remarks about the LeishVet directions for the treatment of canine leishmaniasis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Resistance; Guidelines as Topic; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Treatment Outcome | 2010 |
A 48-year-old man with laryngeal mass and vocal cord palsy.
Topics: Antiprotozoal Agents; HIV Infections; Humans; Laryngeal Diseases; Laryngeal Mucosa; Laryngoscopy; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Vocal Cord Paralysis | 2010 |
Long term follow-up of dogs diagnosed with leishmaniosis (clinical stage II) and treated with meglumine antimoniate and allopurinol.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Follow-Up Studies; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Severity of Illness Index; Time Factors; Treatment Outcome | 2011 |
Disseminated leishmaniasis caused by Leishmania tropica in HIV-positive patients in the Islamic Republic of Iran.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiprotozoal Agents; Biopsy; CD4 Lymphocyte Count; Humans; Immunocompromised Host; Iran; Leishmania tropica; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Risk Factors; Substance Abuse, Intravenous; Travel | 2010 |
Immunotherapy with Imiquimod increases the efficacy of Glucantime therapy of Leishmania major infection.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Antiprotozoal Agents; Drug Therapy, Combination; Imiquimod; Immunotherapy; Leishmania major; Leishmaniasis; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Treatment Outcome | 2011 |
Infectivity to Phlebotomus perniciosus of dogs naturally parasitized with Leishmania infantum after different treatments.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Europe; Female; Humans; Infectious Disease Transmission, Vertical; Leishmania infantum; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phlebotomus; Treatment Outcome | 2011 |
Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages.
Topics: Animals; Antiprotozoal Agents; Cell Survival; Cholesterol; Dose-Response Relationship, Drug; Drug Compounding; Drug Delivery Systems; Excipients; Fluorescence; Humans; Indicators and Reagents; Leishmania major; Leishmaniasis; Liposomes; Macrophages; Male; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred C57BL; Microscopy, Fluorescence; Organometallic Compounds; Oxazines; Phosphatidylserines; Xanthenes | 2011 |
Novel approach to in vitro drug susceptibility assessment of clinical strains of Leishmania spp.
Topics: Antiprotozoal Agents; Cell Line; Humans; Leishmania; Leishmaniasis; Macrophages; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Parasite Load; Parasitic Sensitivity Tests; Phosphorylcholine; Temperature | 2012 |
Novel immunomodulatory function of 1,3,4-thiadiazole derivatives with leishmanicidal activity.
Topics: Animals; Antiprotozoal Agents; Cytokines; Disease Models, Animal; Histocytochemistry; Immunologic Factors; Injections, Intraperitoneal; Leishmaniasis; Liver; Male; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Skin; Spleen; Thiadiazoles; Treatment Outcome | 2012 |
Possible links between sickle cell crisis and pentavalent antimony.
Topics: Anemia, Sickle Cell; Antimony; Child; Glutathione; Humans; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2012 |
Quinolinic alkaloids from Galipea longiflora Krause suppress production of proinflammatory cytokines in vitro and control inflammation in vivo upon Leishmania infection in mice.
Topics: Alkaloids; Animals; Antigens, Protozoan; Antiprotozoal Agents; Cells, Cultured; Cytokines; Female; Immunosuppression Therapy; Inflammation Mediators; Leishmania braziliensis; Leishmaniasis; Lymphocyte Activation; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred C57BL; Organometallic Compounds; Parasite Load; Plant Extracts; Quinolines; Rutaceae; T-Lymphocytes | 2013 |
Effects of the glucantime on the kinetic of biodistribution of radiopharmaceuticals in Wistar rats.
Topics: Animals; Antiprotozoal Agents; Drug Interactions; Humans; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Radiopharmaceuticals; Rats; Rats, Wistar; Technetium Tc 99m Medronate; Tissue Distribution | 2002 |
Inhibition of parasite protein kinase C by new antileishmanial imidazolidin-2-one compounds.
Topics: Animals; Antiprotozoal Agents; Cells, Cultured; Enzyme Inhibitors; Fibroblasts; Humans; Imidazoles; Inhibitory Concentration 50; Leishmania; Leishmaniasis; Liver; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Protein Kinase C; Spleen; Structure-Activity Relationship | 2002 |
[Parenteral glucantime therapy of bouton d'orient, with esthetic results superior to intralesional therapy].
Topics: Antimony; Esthetics; Humans; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1952 |
[N-methylglucamine antimoniate in the treatment of visceral leishmaniasis; first cases treated in Spain].
Topics: Antimony; Humans; Leishmaniasis; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Spain | 1952 |
[Note on the use of drugs with antimony base; a case of kala-azar treated with glucantime].
Topics: Antimony; Hypersensitivity; Immune System Diseases; Leishmaniasis; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1954 |
[The activity of intramuscular glucantime and of intravenous anthiomaline in the treatment of sylvan American leishmaniasis].
Topics: Antimony; Furans; Humans; Leishmaniasis; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1955 |
[Leishmaniasis mucocutaneous americana; our experience in its treatment with glucantime].
Topics: Antimony; Humans; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1955 |
[Two cases of kala-azar treated with glucantime].
Topics: Antimony; Child; Humans; Infant; Leishmaniasis; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1955 |
[Test treatment with N-methylglucamine antimoniate in the diagnosis of kala-azar in children].
Topics: Antimony; Child; Humans; Infant; Leishmaniasis; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1958 |
[8 cases of kala-azar cured with glucantime].
Topics: Antimony; Humans; Leishmaniasis; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1962 |
[N-methylglucamine antimoniate (glucantime) in therapy of infantile visceral leishmaniasis; a further case of autocthonous infantile visceral leishmaniasis on the island of Elba].
Topics: Antimony; Humans; Islands; Leishmaniasis; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1955 |
[Treatment of cutaneous leishmaniasis by antimoniate of N-methyl glucamine; 15 personal observations].
Topics: Humans; Leishmaniasis; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1950 |
[Treatment of kala-azar by glucantime].
Topics: Humans; Leishmaniasis; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1950 |
[Polyneuritic complications after treatment of kala-azar in the adult with 2168 R.P].
Topics: Adult; Humans; Leishmaniasis; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Neuritis; Organometallic Compounds; Polyneuropathies | 1951 |
[Use of glucantime in infantile kala-azar].
Topics: Humans; Leishmaniasis; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1951 |
[American cutaneo-mucous leishmaniasis; glucantime therapy; preliminary note].
Topics: Humans; Leishmaniasis; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; United States | 1951 |
Management of leishmanial osteolytic lesions in a hypothyroid dog by partial tarsal arthrodesis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Arthrodesis; Dog Diseases; Dogs; Hindlimb; Leishmania; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Tarsal Joints; Treatment Outcome | 2004 |
In vitro and in vivo cytotoxicities and antileishmanial activities of thymol and hemisynthetic derivatives.
Topics: Animals; Antiprotozoal Agents; Cricetinae; Female; Humans; Leishmania; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Parasitic Sensitivity Tests; Structure-Activity Relationship; Terpenes; Thymol; U937 Cells | 2005 |
Granulomatous lesion on a bitch's nipple caused by Leishmania infantum.
Topics: Allopurinol; Animals; Breast Diseases; Dog Diseases; Dogs; Female; Leishmania infantum; Leishmaniasis; Meglumine; Meglumine Antimoniate; Nipples; Organometallic Compounds | 2005 |
Role of residual Sb(III) in meglumine antimoniate cytotoxicity and MRP1-mediated resistance.
Topics: Animals; Antimony; Antiprotozoal Agents; Cations; Cell Line; Drug Resistance, Microbial; Leishmania; Leishmaniasis; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Multidrug Resistance-Associated Proteins; Organometallic Compounds | 2006 |
Characterization of reactions of antimoniate and meglumine antimoniate with a guanine ribonucleoside at different pH.
Topics: Animals; Antimony; Antiprotozoal Agents; Guanosine Monophosphate; Hydrogen-Ion Concentration; Leishmaniasis; Meglumine; Meglumine Antimoniate; Nuclear Magnetic Resonance, Biomolecular; Organometallic Compounds; Spectrometry, Mass, Electrospray Ionization; Thermodynamics | 2006 |
Canine leishmaniasis chemotherapy: dog's clinical condition and risk of Leishmania transmission.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Bone Marrow; Disease Transmission, Infectious; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Recurrence; Skin; Treatment Outcome; Trifluralin | 2006 |
[Symptomatic hypokalemia caused by meglumine antimoniate].
Topics: Antiprotozoal Agents; Female; Humans; Hypokalemia; Injections, Intramuscular; Leishmaniasis; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds | 2007 |
Real-time PCR assay in Leishmania-infected dogs treated with meglumine antimoniate and allopurinol.
Topics: Allopurinol; Animals; Antiprotozoal Agents; DNA, Protozoan; Dog Diseases; Dogs; Drug Therapy, Combination; Leishmania; Leishmaniasis; Lymph Nodes; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Polymerase Chain Reaction; Skin | 2008 |
Pentoxifylline prevents the meglumine antimonate-induced renal toxicity in rats, but not that induced by the inorganic antimony pentachloride.
Topics: Animals; Antimony; Antiprotozoal Agents; Chlorides; Dose-Response Relationship, Drug; Kidney Diseases; Kidney Function Tests; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Pentoxifylline; Phosphodiesterase Inhibitors; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha | 2008 |
Short communication: The cost-effectiveness of cutaneous leishmaniasis patient management during an epidemic in Chaparral, Colombia in 2004.
Topics: Antiprotozoal Agents; Colombia; Cost-Benefit Analysis; Disease Outbreaks; Hospital Costs; Humans; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2007 |
Leishmaniasis recidivans treated with sodium stibogluconate.
Topics: Adult; Anti-Bacterial Agents; Antimony; Antimony Sodium Gluconate; Gluconates; Humans; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Recurrence | 1981 |
[Cutaneous leishmaniasis in patients returning from the tropics].
Topics: Adolescent; Adult; Aged; Antimony; Antiprotozoal Agents; Benzenesulfonates; Female; Humans; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Sulfamethoxazole; Travel; Tropical Climate | 1984 |
[Successful intralesional treatment of leishmaniasis caused by Leishmania brasiliensis panamensis using glucantime].
Topics: Adolescent; Adult; Aged; Antimony; Child; Child, Preschool; Drug Evaluation; Female; Humans; Infant; Infant, Newborn; Leishmania; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds | 1984 |
[Experimental chemotherapy in cutaneous leishmaniasis. III. Effect of glucantime and humatin (P&D) on Leishmania garnhami and Leishmania braziliensis in hamsters].
Topics: Animals; Antimony; Antiprotozoal Agents; Cricetinae; Drug Therapy, Combination; Female; Leishmania; Leishmaniasis; Leishmaniasis, Mucocutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Paromomycin; Sex Factors | 1984 |
Toxicity and efficacy of the antileishmanial drug meglumine antimoniate in the owl monkey (Aotus trivirgatus).
Topics: Animals; Antimony; Antiprotozoal Agents; Aotus trivirgatus; Cebidae; Female; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Monkey Diseases; Organometallic Compounds | 1983 |
Cutaneous leishmaniasis in mice: resistance to glucan immunotherapy, either alone or combined with chemotherapy.
Topics: Animals; Antimony; Dose-Response Relationship, Immunologic; Female; Glucans; Immunotherapy; Leishmaniasis; Leishmaniasis, Mucocutaneous; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred C57BL; Mononuclear Phagocyte System; Organometallic Compounds; Sorbitol | 1982 |
Disposition of antimony and aminosidine in dogs after administration separately and together: implications for therapy of leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Interactions; Female; Injections, Subcutaneous; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Models, Biological; Organometallic Compounds; Paromomycin | 1995 |
[Leishmaniasis and ENT].
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Animals; Diagnosis, Differential; Enzyme-Linked Immunosorbent Assay; Humans; Hypopharynx; Larynx; Leishmania; Leishmaniasis; Male; Meglumine; Paranasal Sinuses | 1995 |
Antimony determination in tissues and serum of hamsters infected with Leishmania garnhami and treated with meglumine antimoniate.
Topics: Animals; Antimony; Antiprotozoal Agents; Cricetinae; Injections, Intralesional; Injections, Intramuscular; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Mesocricetus; Organometallic Compounds; Tissue Distribution | 1994 |
Synthesis of antimony complexes of yeast mannan and mannan derivatives and their effect on Leishmania-infected macrophages.
Topics: Animals; Antimony; Antiprotozoal Agents; Carbohydrate Sequence; Cricetinae; Drug Carriers; Lectins, C-Type; Leishmania; Leishmaniasis; Macrophages; Mannans; Mannose; Mannose Receptor; Mannose-Binding Lectins; Meglumine; Meglumine Antimoniate; Mice; Molecular Sequence Data; Organometallic Compounds; Receptors, Cell Surface; Receptors, Immunologic; Saccharomyces cerevisiae | 1993 |
2-substituted quinoline alkaloids as potential antileishmanial drugs.
Topics: Alkaloids; Animals; Antiprotozoal Agents; Female; Leishmania; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Quinolines | 1993 |
Nitric oxide production in murine leishmaniasis: correlation of progressive infection with increasing systemic synthesis of nitric oxide.
Topics: Animals; Antiprotozoal Agents; Body Weight; Disease Progression; Injections, Intraperitoneal; Leishmaniasis; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Nitric Oxide; Organometallic Compounds; Species Specificity | 1996 |
Pharmacokinetics of liposome-encapsulated meglumine antimonate after intramuscular and subcutaneous administration in dogs.
Topics: Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Carriers; Injections, Intramuscular; Injections, Subcutaneous; Leishmaniasis; Liposomes; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1997 |
[Torsade de pointes secondary to treatment with pentavalent antimonial drugs].
Topics: Adult; Antiprotozoal Agents; Humans; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Torsades de Pointes | 1998 |
Effects of antimonial therapy for canine leishmaniasis on antibody titer.
Topics: Allopurinol; Animals; Antibodies, Protozoan; Antimony; Antiprotozoal Agents; Dog Diseases; Dogs; Fluorescent Antibody Technique, Indirect; Follow-Up Studies; Injections, Intramuscular; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Regression Analysis; Time Factors | 1998 |
Genital ulcer in an AIDS patient with disseminated leishmaniasis.
Topics: Adult; AIDS-Related Opportunistic Infections; Animals; Antiprotozoal Agents; Foot Ulcer; Humans; Leishmania; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Penile Diseases; Ulcer | 1998 |
Physico-chemical characterization of meglumine antimoniate.
Topics: Antiprotozoal Agents; Hydrogen-Ion Concentration; Leishmaniasis; Magnetic Resonance Spectroscopy; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Potentiometry | 1999 |
[Torsades de pointes during treatment of leishmaniasis with meglumine antimoniate].
Topics: Aged; Antimony; Antiprotozoal Agents; Electrocardiography; Female; Humans; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Torsades de Pointes | 1999 |
[A 34-year-old man with lingual tumor. Lingual leishmaniasis in a patient with HIV infection].
Topics: Adult; AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Diagnosis, Differential; Humans; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Time Factors; Tongue Diseases; Treatment Outcome | 2001 |
Monitoring of total antimony and its species by ICP-MS and on-line ion chromatography in biological samples from patients treated for leishmaniasis.
Topics: Adult; Antimony; Antiprotozoal Agents; Chromatography, Ion Exchange; Gas Chromatography-Mass Spectrometry; Hair; Humans; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds | 2002 |
Leishmaniasis of the prepuce.
Topics: Antiprotozoal Agents; Diagnosis, Differential; Humans; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Penile Diseases | 2002 |
In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate.
Topics: Animals; Antimony; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Resistance; Humans; Leishmania infantum; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Parasitic Sensitivity Tests | 2002 |
Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs.
Topics: Animals; Antimony; Antimony Sodium Gluconate; Cricetinae; Disease Models, Animal; Gluconates; Leishmaniasis; Liposomes; Liver; Meglumine; Pharmaceutical Vehicles; Phospholipids; Structure-Activity Relationship; Surface Properties | 1978 |
Improved therapy of experimental leishmaniasis by use of a liposome-encapsulated antimonial drug.
Topics: Animals; Cricetinae; Leishmaniasis; Liposomes; Meglumine; Mesocricetus; Sorbitol; Time Factors | 1978 |
Interferon gamma therapy for cutaneous leishmaniasis.
Topics: Animals; Antimony; Antiprotozoal Agents; Humans; Interferon-gamma; Leishmania tropica; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Recombinant Proteins | 1990 |
Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania ssp. from patients unresponsive to pentavalent antimony therapy.
Topics: Adenosine; Animals; Antimony Sodium Gluconate; Drug Resistance; Eflornithine; Leishmania; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1990 |
Diffuse cutaneous leishmaniasis acquired in Peru.
Topics: Adult; Antimony; Antiprotozoal Agents; Biopsy; Female; Humans; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Peru; Skin | 1990 |
[Cutaneous leishmaniasis: treatment with cryotherapy and intramuscular injections of meglumine antimonate (glucantime)].
Topics: Adult; Combined Modality Therapy; Cryosurgery; Female; Humans; Injections, Intramuscular; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Otitis Externa; Sorbitol | 1990 |
Retention of antimony in skin biopsies of leishmaniasis patients after treatment with N-methylglucamine antimoniate.
Topics: Adolescent; Adult; Aged; Antimony; Biopsy; Child; Double-Blind Method; Drug Administration Schedule; Humans; Injections, Intravenous; Leishmaniasis; Meglumine; Meglumine Antimoniate; Middle Aged; Neutron Activation Analysis; Organometallic Compounds; Random Allocation; Skin; Sorbitol | 1990 |
Berberine derivatives as antileishmanial drugs.
Topics: Animals; Antiprotozoal Agents; Berberine; Berberine Alkaloids; Body Weight; Cricetinae; Leishmaniasis; Leishmaniasis, Mucocutaneous; Leishmaniasis, Visceral; Liver; Meglumine; Meglumine Antimoniate; Mesocricetus; Organometallic Compounds; Skin | 1990 |
Leishmaniasis. A worldwide problem.
Topics: Antimony Sodium Gluconate; Humans; Leishmaniasis; Meglumine | 1989 |
[Cutaneous leishmaniasis].
Topics: Antimony; Antimony Sodium Gluconate; Antiprotozoal Agents; Child; Humans; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1989 |
An in vitro micromethod for drug sensitivity testing of Leishmania.
Topics: Animals; Antimony; Antimony Sodium Gluconate; Antiprotozoal Agents; Culture Media; Gluconates; Humans; Least-Squares Analysis; Leishmania; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Regression Analysis; Sorbitol; Time Factors | 1989 |
[Evaluation of the effectiveness and toxicity of pentostam and glucantime in the treatment of cutaneous leishmaniasis].
Topics: Adult; Antimony Sodium Gluconate; Drug Evaluation; Female; Gluconates; Humans; Immunologic Techniques; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Random Allocation; Sorbitol | 1987 |
Pentavalent antimonial treatment in mucosal leishmaniasis.
Topics: Antimony; Drug Administration Schedule; Humans; Leishmaniasis; Meglumine; Meglumine Antimoniate; Nifurtimox; Nitrofurans; Organometallic Compounds | 1985 |
Recurrences of tegumentary leishmaniasis.
Topics: Antimony; Antiprotozoal Agents; Child; Humans; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Recurrence | 1985 |
Kala azar with disseminated dermal leishmaniasis.
Topics: Adolescent; Antiprotozoal Agents; Biopsy; Child; Female; Humans; Iran; Leishmaniasis; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Skin; Sorbitol | 1989 |
[Methylglucamine antimoniate and sodium stibogluconate in the treatment of leishmaniasis. Study of 16 cases].
Topics: Adolescent; Adult; Antimony; Antimony Sodium Gluconate; Child; Child, Preschool; Female; Gluconates; Humans; Infant; Leishmaniasis; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Pentamidine; Splenectomy | 1985 |
Glomerulonephritis in dogs with canine leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Complement C3; Dog Diseases; Dogs; Glomerulonephritis; Immunoglobulin G; Kidney; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1988 |
[Leishmaniasis of the genital organs].
Topics: Adult; Aged; Animals; Antiprotozoal Agents; Humans; Leishmania braziliensis; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Penile Diseases; Penile Neoplasms | 1987 |
Cutaneous leishmaniasis in Bolivia. A study of 185 human cases from Alto Beni (La Paz Department). Isolation and isoenzyme characterization of 26 strains of Leishmania braziliensis braziliensis [corrected].
Topics: Animals; Antiprotozoal Agents; Bolivia; Cricetinae; Humans; Leishmania; Leishmania braziliensis; Leishmaniasis; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Skin | 1987 |
[Culture systems for production of promastigote and amastigote forms of Leishmania. Application to serological diagnosis and therapeutic trials].
Topics: Animals; Antimony; Antiprotozoal Agents; Cell Line; Culture Media; Fluorescent Antibody Technique; Leishmania; Leishmaniasis; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Serologic Tests; Time Factors | 1986 |
The development of a vaccination model using two microorganisms and its application in leprosy and leishmaniasis.
Topics: Humans; Immunotherapy; Leishmania mexicana; Leishmaniasis; Leprosy; Meglumine; Meglumine Antimoniate; Mycobacterium leprae; Organometallic Compounds; Vaccination | 1986 |
In vitro and in vivo anti-leishmanial activity of chlorpromazine alone and combined with N-meglumine antimonate.
Topics: Animals; Antiprotozoal Agents; Chlorpromazine; Drug Therapy, Combination; Leishmania; Leishmaniasis; Macrophages; Male; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Organometallic Compounds; Sorbitol; Spleen | 1986 |
Disseminated cutaneous leishmaniasis in a field clinic in Bahia, Brazil: a report of eight cases.
Topics: Adolescent; Adult; Aged; Antimony; Antiprotozoal Agents; Brazil; Humans; Leishmaniasis; Leishmaniasis, Mucocutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1986 |